cd70 car-nk
Cell therapyexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2024 (NCT06696846)
Timeline
Indications
Mechanism of action
- CD70 antigenImmunity, passive
CD70 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07164469 | Phase 2 | Feb 28, 2026 | Bellicum Pharmaceuticals, University of Texas at Houston |
| NCT07072234 | Phase 1 | Sep 25, 2025 | University of Texas at Houston |
| NCT06696846 | Phase 1 | Dec 1, 2024 | Zhejiang University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Texas at Houston | Academic/Hospital | 2 | 2 | 2 | 2025 |
| Bellicum Pharmaceuticals | For profit | 1 | 0 | 1 | 2026 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1